| Hypertension |
2008-007516-15: Comparaison des effets du nébivolol et de l\'aténolol sur la fonction endothéliale vasomotrice des artères de conductance lors de l\'hypertension artérielle essentielle |
|
|
| Ongoing | 4 | 100 | Europe | NEBILOX, ATENOLOL BIOGARAN 50 mg, NEBILOX, ATENOLOL BIOGARAN 50 mg | Laboratoires NEGMA | Hypertension artérielle | | | | |
2011-002587-24: Effect of Aliskiren drug in patients with high blood pressure Effetto del farmaco Aliskiren in pazienti con pressione alta |
|
|
| Ongoing | 4 | 42 | Europe | ENALAPRIL S.G.*28CPR 5MG, RASILEZ*56CPR RIV 150MG, ENALAPRIL S.G.*28CPR 5MG, RASILEZ*56CPR RIV 150MG | FONDAZIONE CENTRO S. RAFFAELE DEL MONTE TABOR, Novartis | dysfunction of coronary microcirculation in arterial hypertension disfunzione del microcircolo coronarico nell\'ipertensione arteriosa | | | | |
2016-000501-36: An unblinded long-term extension study in different countries and centers on orally administered riociguat in patients with symptomatic pulmonary arterial hypertension (PAH) who received riociguat in a Bayer clinical trial |
|
|
| Not yet recruiting | 4 | 20 | Europe | Adempas 0.5 mg, Adempas 1.0 mg, Adempas 1.5 mg, Adempas 2.0 mg, Adempas 2.5 mg, BAY63-2521, Film-coated tablet, Adempas | Bayer HealthCare, BAYER AG, Bayer HealthCare | Hypertension, Pulmonary, Pulmonary arterial hypertension (PAH), Diseases [C] - Cardiovascular Diseases [C14] | | | | |
| Not yet recruiting | 4 | 66 | Europe | ALLOPURINOL, n/a, Capsule, hard | University of Dundee/NHS Tayside, British Heart Foundation Grant Funding | Left ventricular hypertrophy in hypertension, Enlarged heart associated with previous high blood pressure, Diseases [C] - Cardiovascular Diseases [C14] | | | | |
2015-002078-19: Prospective, multicenter, open-label study evaluating the effects of first-line oral combination therapy of macitentan and tadalafil in patients with newly diagnosed pulmonary arterial hypertension Etude prospective, multicentrique, en ouvert, évaluant les effets de l'association thérapeutique en 1ère ligne du macitentan et du tadalafil par voie orale chez des patients avec HTAP nouvellement diagnostiquée |
|
|
| Not yet recruiting | 4 | 60 | Europe | macitentan, tadalafil, ACT-064992, Film-coated tablet, Opsumit, Adcirca | ACTELION Pharmaceuticals France, ACTELION Pharmaceuticals France | Pulmonary arterial hypertension Hypertension artérielle pulmonaire, Pulmonary arterial hypertension Hypertension artérielle pulmonaire, Diseases [C] - Respiratory Tract Diseases [C08] | | | | |
2017-003672-31: Fixed-dose combination of rosuvastatin and valsartan for dual target achievement in patients with hypertension and hyperlipidaemia (UNIFY) |
|
|
| Not yet recruiting | 4 | 280 | Europe | Ravalsyo, Film-coated tablet, Ravalsyo® | KRKA, d.d., Novo mesto, KRKA d.d., Novo mesto | Patients with mild to moderate essential arterial hypertension AND primary hypercholesterolemia or mixed dyslipidaemia (LDL-c < 4.9 mmol/L or <189.5 mg/dl) with moderate, high or very high risk for cardiovascular event., Patients with mild to moderate essential arterial hypertension AND primary hypercholesterolemia or mixed dyslipidaemia with moderate, high or very high risk for cardiovascular event., Diseases [C] - Cardiovascular Diseases [C14] | | | | |
2019-001030-34: A Prospective Open-label, Multicentric, Phase IV Trial to Compare the Efficacy of 10-Week Therapy of Ramipril and Indapamide SR Tablets Given Concomitantly with that of the Monotherapy of Ramipril or Indapamide SR in the Treatment of Hypertensive Patients whose Blood Pressure is Not Controlled by Monotherapy |
|
|
| Not yet recruiting | 4 | 221 | Europe | Tritace, Pretanix 1,5 mg retard filmtabletta, Tablet, Film-coated tablet, Tritace 2,5 mg tabletta, Tritace 5 mg tabletta, Tritace 10 mg tabletta, Pretanix 1,5 mg retard filmtabletta, Tensiomin | Egis Pharmaceuticals PLC, Egis Pharmaceuticals PLC | hypertension, elevated blood pressure, Diseases [C] - Cardiovascular Diseases [C14] | | | | |
2020-002340-23: Effectiveness and safety of combination of nebivolol and zofenopril calcium in mild to moderate hypertensive patients Efficacia e sicurezza della combinazione di nebivololo e zofenopril calcio in pazienti affetti da ipertensione da lieve a moderata |
|
|
| Not yet recruiting | 4 | 216 | Europe | Nebivolol, Zofenopril calcium, [na], Tablet, Film-coated tablet, LOBIVON - 28 COMPRESSE 5 MG, ZOPRANOL - 28 COMPRESSE RIVESTITE CON FILM 30 MG IN BLISTER (PVDC/PVC/AL) | MENARINI INTERNATIONAL OPERATIONS LUXEMBOURG SA, Menarini International Operations Luxembourg SA | Grade 1 and 2 hypertension Ipertenzione di grado 1 e 2, Hypertension Ipertensione, Diseases [C] - Cardiovascular Diseases [C14] | | | | |
| Terminated | 4 | 20 | RoW | Brevibloc, 10 Mg/mL Intravenous Solution, Brevibloc, Nitroprusside, Sodium, Nitroprus | Cristália Produtos Químicos Farmacêuticos Ltda. | Hemorrhagic Stroke | 10/21 | 10/21 | | |
NCT05065892: Evaluation of Immunogenicity and Safety of COVID-19 Vaccine (Produced in Wuhan) in Patients With Hypertension and/or Diabetes |
|
|
| Not yet recruiting | 4 | 1440 | RoW | COVAX | China National Biotec Group Company Limited, Guizhou Center for Disease Control and Prevention, Hunan Center for Disease Control and Prevention, Fujian Center for Disease Control and Prevention, Wuhan Institute of Biological Products Co., Ltd | COVID-19 Pneumonia | 01/22 | 03/22 | | |
2021-000745-40: Clinical trial to assess efficacy and safety of the combination of Zofenopril calcium and amlodipine in grade 1-2 hypertensive patients versus each single drug therapy Studio clinico per valutare l’efficacia e la sicurezza della combinazione di Zofenopril calcio e amlodipina in pazienti con ipertensione di grado 1-2 rispetto a ciascuna monoterapia |
|
|
| Not yet recruiting | 4 | 290 | Europe | Zofenopril calcium, not applicable, [not applicable], Film-coated tablet, Tablet, ZOPRANOL - 28 COMPRESSE RIVESTITE CON FILM 30 MG IN BLISTER (PVDC/PVC/AL), AMLODIPINA EUROGENERICI - 5 MG COMPRESSE 14 COMPRESSE IN BLISTER AL/PVC/PE/PVDC, AMLODIPINA EUROGENERICI - 10 MG COMPRESSE 14 COMPRESSE IN BLISTER AL/PVC/PE/PVDC | MENARINI INTERNATIONAL OPERATIONS LUXEMBOURG SA, Menarini International Operations Luxembourg SA | Grade 1-2 hypertension Ipertensione di grado 1-2, Hypertension Ipertensione, Diseases [C] - Cardiovascular Diseases [C14] | | | | |
2021-003407-17: Combined effects of potassium, nitrate and sodium on blood pressure in patients with hypertension Kombinerede effekter af kalium, nitrat og salt på blodtrykket hos patienter med forhøjet blodtryk |
|
|
| Ongoing | 4 | 120 | Europe | Kaliumklorid "Orifarm", Tablet, Kaliumklorid "Orifarm" | University Clinic of Nephrology and Hypertension, University Clinic of Nephrology and Hypertension | Essential Hypertension Essentiel hypertension, Hypertension Forhøjet blodtryk, Body processes [G] - Circulatory and Respiratory Physiological Phenomena [G09] | | | | |
2021-006752-14: Program with Medically assisted Rapid Weight Loss as treatment of Idiopathic Intracranial Hypertension Hurtigt vægttab assisteret med medicin som behandling for idiopatisk intrkraniel hypertension |
|
|
| Not yet recruiting | 4 | 50 | Europe | Ozempic, Injection, Ozempic | Rigshospitalet, Neurologisk afdeling, Novo Nordisk Foundation | Idiopathic Intracranial Hypertension (IIH) is a disease in which the intracranial pressure is pathologically elevated. This can cause blindness, chronic, severe headache, and cognitive dysfunction. IIH is associated with obesity, and the only treatment which controls the disease is weight loss. Idiopatisk intrakraniel hypertension er en relativt sjælden tilstand, hvor væsketrykket i hjernen er forhøjet. Patienter med IIH risikerer synsstab, kronisk hovedpine og koncentrationsbesvær. IIH behandles med vægttab og vanddrivende medicin. Den eneste kendte behandling, der reelt ændrer på sygdommens aktivitet, er vægttab., Idiopathic Intracranial Hypertension (IIH) is a disease in which the brain pressure is elevated. This can cause blindness, chronic, severe headache, and cognitive dysfunction. Idiopatisk intrakraniel hypertension er en relativt sjælden tilstand, hvor væsketrykket i hjernen er forhøjet. Patienter med IIH risikerer synsstab, kronisk hovedpine og koncentrationsbesvær., Diseases [C] - Nervous System Diseases [C10] | | | | |
PEARL, NCT04073290: Prevention of Post-TIPS Hepatic Encephalopathy by Administration of Rifaximin and Lactulose |
|
|
| Recruiting | 4 | 238 | Europe | Rifaximin 550 milligram Oral Tablet [XIFAXAN], TARGAXAN, Placebo oral tablet, Placebo, Lactulose 667 milligram/milliliter Oral Solution, Lactulose syrup | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), Erasmus Medical Center, Leiden University Medical Center, Maastricht University Medical Center, Radboud University Medical Center, University Medical Center Groningen, Universitaire Ziekenhuizen Leuven, Norgine | Hepatic Encephalopathy, Cirrhosis, Liver, Portal Hypertension, Liver Diseases, Pathological Processes | 09/22 | 09/23 | | |
NCT04457323: S-Metoprolol XR 25-50 mg Tablets vs Metoprolol Zok 50-100 mg Tablets in Hypertension Patients. |
|
|
| Not yet recruiting | 4 | 126 | NA | Metoprolol, S-metoprolol | Neutec Ar-Ge San ve Tic A.Åž | Hypertension | 10/22 | 12/22 | | |
NCT05104437: Evaluation of Immunogenicity, Safety and Antibody Persistence of COVID-19 Booster Vaccine (Produced in Wuhan) in Patients With Hypertension and/or Diabetes |
|
|
| Not yet recruiting | 4 | 1440 | RoW | Covid-19 vaccine (0-1-4 schedule), Covid-19 vaccine (0-1-6 schedule) | China National Biotec Group Company Limited, Guizhou Center for Disease Control and Prevention, Hunan Center for Disease Control and Prevention, Fujian Center for Disease Control and Prevention, Wuhan Institute of Biological Products Co., Ltd | COVID-19 Pneumonia | 11/22 | 12/22 | | |
NCT05104333: Evaluation of Immunogenicity, Safety and Antibody Persistence of COVID-19 Booster Vaccine (Produced in Beijing) in Patients With Hypertension and/or Diabetes |
|
|
| Not yet recruiting | 4 | 1440 | RoW | Covid-19 vaccine (0-1-4 schedule), Covid-19 vaccine (0-1-6 schedule) | China National Biotec Group Company Limited, Guizhou Center for Disease Control and Prevention, Hunan Center for Disease Control and Prevention, Fujian Center for Disease Control and Prevention, Beijing Institute of Biological Products Co Ltd. | COVID-19 Pneumonia | 11/22 | 12/22 | | |
2021-005077-10: Study on the effectiveness and safety of combined treatment with nebivolol and amlodipine in mild to moderate hypertensive patients. |
|
|
| Not yet recruiting | 4 | 302 | Europe | Nebivolol, Amlodipine, Tablet, LOBIVON 5 mg tablets, AMLODIPINE EUROGENERIC 5 mg tablets, AMLODIPINE EUROGENERIC 10 mg tablets | Menarini International Operations Luxembourg SA, Menarini International Operations Luxembourg SA | Grade 1-2 hypertension, Hypertension, Diseases [C] - Cardiovascular Diseases [C14] | | | | |
Botticelli, NCT05513937: Effectiveness and Safety of Combination of Nebivolol and Amlodipine in Hypertensive Patients Versus Each Monotherapy |
|
|
| Completed | 4 | 291 | Europe | Nebivolol, Amlodipine | Menarini International Operations Luxembourg SA | Hypertension | 11/22 | 11/22 | | |
| Terminated | 4 | 232 | Europe, Canada, Japan, US, RoW | PAH Therapies | Actelion | Pulmonary Arterial Hypertension | 12/22 | 12/22 | | |
2022-003060-25: Study on the effectiveness and safety of combined treatment with Nebivolol and Ramipril in hypertensive patients |
|
|
| Ongoing | 4 | 270 | Europe | Nebivolol, Ramipril, Tablet, LOBIVON 5 mg tablets, Ramipril Zentiva 2.5 mg, Ramipril Zentiva 5 mg, Ramipril Zentiva 10 mg | Menarini International Operations Luxembourg SA, Menarini International Operations Luxembourg SA | Cardiovascular DiseaseHypertensive patients, Hypertension, Diseases [C] - Cardiovascular Diseases [C14] | | | | |
NCT06431477: Efficacy and Safety of Telmisartan Compared With Losartan |
|
|
| Recruiting | 4 | 98 | RoW | telmisartan, Losartan | Chong Kun Dang Pharmaceutical | Diabetic Nephropathies, Hypertension | 10/25 | 10/25 | | |
NCT04908982: Aspirin for the Prevention of Preeclampsia in Women With Stage 1 Hypertension |
|
|
| Recruiting | 4 | 60 | US | Aspirin 81mg | Eastern Virginia Medical School, AMAG Pharmaceuticals, Inc. | Pre-Eclampsia | 05/23 | 05/23 | | |
2019-004783-22: A clinical trial to study the effects of selexipag on the heart in patients with Pulmonary Arterial Hypertension |
|
|
| Not yet recruiting | 4 | 80 | Europe, RoW | Uptravi, ACT-293987, Film-coated tablet, Uptravi | ACTELION Pharmaceuticals Ltd., Actelion Pharmaceuticals Ltd | Pulmonary Arterial Hypertension, Pulmonary arterial hypertension (PAH) is a serious chronic disorder of the pulmonary circulation, Diseases [C] - Respiratory Tract Diseases [C08] | | | | |
RESTORE, NCT04435782: A Study of Selexipag Assessing Right Ventricular Remodeling in Pulmonary Arterial Hypertension by Cardiac Magnetic Resonance Imaging |
|
|
| Terminated | 4 | 9 | Europe, US, RoW | JNJ-67896049, Selexipag | Actelion | Pulmonary Arterial Hypertension | 07/23 | 07/23 | | |
TripleTRE, NCT06317805: Initial Triple Therapy Including Parenteral Treprostinil vs Initial Double Oral Therapy in PAH Group I Patients |
|
|
| Recruiting | 4 | 110 | Europe, RoW | Generic treprostinil sodium + Standard of Care (Double Oral), Trisuva, Tresuvi, Treposa, Treprostinil Orpha-Devel, Treprostinil Amomed, Treprostinil OrPha, Treposuvi, Standard of Care - Double Oral | AOP Orphan Pharmaceuticals AG, ANOVA CRO s.r.o., PharmaLex Belgium, Aixial s.r.o., GCP-Service International Ltd. & Co. KG | Pulmonary Arterial Hypertension | 06/27 | 06/27 | | |
PRISTINE, NCT05843162: A Clinical Trial to Evaluate the Blood Pressure Control of Telmisartan or Losartan in Essential Hypertensive Patients With Metabolic Syndrome |
|
|
| Not yet recruiting | 4 | 116 | NA | Telmisartan, Losartan | Chong Kun Dang Pharmaceutical | Essential Hypertension, Metabolic Syndrome | 12/23 | 12/23 | | |
| Recruiting | 4 | 50 | Europe | Patiromer 8400 MG [Veltassa], Placebo | University Medical Center Groningen, Amsterdam University Medical Center, Medical Centre Leeuwarden, Isala, Vifor Pharma, Inc., Dutch Kidney Foundation, Health Holland | Chronic Kidney Diseases, Hyperkalemia, Hypertension | 12/26 | 12/26 | | |
ARTEMISIA, NCT06104423 / 2022-003060-25: Open-label, Multicenter, multinAtionaL, inteRventional Clinical Trial to Assess Efficacy and Safety of the exteMporaneous combInation of Nebivolol and Ramipril in hypertenSIve pAtients |
|
|
| Recruiting | 4 | 215 | Europe | Nebivolol 5 mg, Ramipril 2.5/5/10 mg | Menarini International Operations Luxembourg SA, Menarini International Operations Luxembourg SA | Hypertension | 05/24 | 05/24 | | |
BETTER, NCT05880056: Study of Bisoprolol (Nerkardou - Nerhadou International) 5 and 10 mg Oral Dissolvable Film (ODF) Treatment in Egyptian Patients With Essential Hypertension |
|
|
| Recruiting | 4 | 406 | RoW | Nerkardou (5 mg) & (10 mg), Bisoprolol oral dissolved film ODF (5 mg) & (10 mg) | Genuine Research Center, Egypt, Nerhadou International for pharmaceutical & Nutraceutical, Egypt | Essential Hypertension | 04/25 | 04/25 | | |
DESIGN, NCT05727579: DiEtary Sodium Intake Effects on Ertugliflozin-induced Changes in GFR, reNal Oxygenation and Systemic Hemodynamics: the Study |
|
|
| Not yet recruiting | 4 | 34 | NA | Salt-Diet and/or Ertugliflozin | Amsterdam UMC, location VUmc, Merck Sharp & Dohme LLC, University of Colorado, Denver | Diabetes Mellitus, Diabetic Kidney Disease, Hypertension | 09/24 | 03/25 | | |
ARTISAN, NCT05203510: A Study of a Mean Pulmonary Artery Pressure-Targeted Approach With Early and Rapid Treprostinil Therapy to Reverse Right Ventricular Remodeling in Participants With Pulmonary Arterial Hypertension |
|
|
| Recruiting | 4 | 50 | US | Parenteral Treprostinil, Remodulin, Oral Treprostinil, Orenitram | United Therapeutics, Lung Biotechnology PBC | Pulmonary Arterial Hypertension | 12/24 | 12/27 | | |
NCT06041529: Study to Evaluate the Efficacy and Safety of TEL/AML/CTD in Elderly Patients With Essential Hypertension |
|
|
| Not yet recruiting | 4 | 250 | RoW | Telmisartan/Amlodipine/Chlorthalidone 40/5/12.5 mg, Truset 40/5/12.5mg, Telmisartan/Amlodipine/Hydrochlorothiazide 40/5/25 mg, Twynsta 40/5 mg, Dichlozid 25 mg | Yuhan Corporation | Essential Hypertension | 02/25 | 06/25 | | |
RIALTO, NCT02759419: A Long-term Extension Study of Riociguat in Patients With Symptomatic Pulmonary Arterial Hypertension. |
|
|
| Recruiting | 4 | 25 | Europe, RoW | Adempas (Riociguat, BAY63-2521) | Bayer | Hypertension, Pulmonary | 12/25 | 12/25 | | |
| Recruiting | 4 | 30 | Europe | Riociguat, MK-4836, ATC code: C02KX05 | Heidelberg University, Merck Sharp & Dohme LLC | Primary Pulmonary Arterial Hypertension, Chronic Thromboembolic Pulmonary Hypertension | 03/26 | 03/26 | | |
CSPPT2-TT, NCT04974151: China Stroke Primary Prevention Trial 2 for Participants With Hypertension and MTHFR 677 TT Genotype |
|
|
| Not yet recruiting | 4 | 24000 | RoW | Amlodipine besylate, Amlodipine, Amlodipine besylate And Folic Acid, Amlodipine Folic Acid, Anye, 5-methyltetrahydrofolate (5-MTHF), 5-MTHF, Amlodipine placebo, Amlodipine (dummy), Amlodipine folic acid placebo, Amlodipine folic acid (dummy), 5-MTHF Placebos, 5-MTHF (dummy) | Shenzhen Ausa Pharmed Co.,Ltd, Peking University First Hospital, Second Affiliated Hospital of Nanchang University, The First People's Hospital of Lianyungang, The First Affiliated Hospital of Shanxi Medical University, The Affiliated Hospital Of Guizhou Medical University, H & J CRO International, Inc., Shenzhen Prospective Medical Technology Co., LTD | Hypertension, MTHFR 677 TT Genotype | 06/29 | 06/29 | | |
CSPPT2-CC/CT, NCT04974138: China Stroke Primary Prevention Trial 2 for Participants With H-type Hypertension and MTHFR 677 CC/CT Genotype |
|
|
| Not yet recruiting | 4 | 32000 | RoW | Amlodipine besylate, Amlodipine, Amlodipine besylate and folic acid, Amlodipine folic acid, Anye, Amlodipine placebos, Amlodipine (dummy), Amlodipine-folic acid placebos, Amlodipine-folic acid (dummy) | Shenzhen Ausa Pharmed Co.,Ltd, Peking University First Hospital, Second Affiliated Hospital of Nanchang University, The First People's Hospital of Lianyungang, The First Affiliated Hospital of Shanxi Medical University, The Affiliated Hospital Of Guizhou Medical University, H & J CRO International, Inc., Shenzhen Prospective Medical Technology Co., LTD | Hypertension, MTHFR 677 CC or CT Genotype, Elevated Plasma Homocysteine (Hcy≥10µmol/L), Insufficient Plasma Folate Levels (<12ng/mL) | 06/29 | 06/29 | | |
2015-004164-11: Effect of the glucose-lowering drug dapagliflozin on vascular function and blood pressure Effetto dell’antidiabetico orale dapagliflozin sulla funzione vascolare e sulla pressione arteriosa |
|
|
| Ongoing | 3 | 55 | Europe | FORXIGA, ESIDREX, NON DISPONIBILE, Film-coated tablet, Tablet, FORXIGA - 10 MG - COMPRESSE RIVESTITE CON FILM- USO ORALE - BLISTER CALENDARIZZATO (ALU/ALU) - 28 COMPRESSE, ESIDREX - 25 MG COMPRESSE 20 COMPRESSE | AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA, AstraZeneca S.p.A | Arterial hypertension Ipertensione arteriosa, Arterial hypertension Ipertensione arteriosa, Diseases [C] - Cardiovascular Diseases [C14] | | | | |
| No Longer Available | 3 | | Japan, US, Canada, Europe, RoW | Adempas (Riociguat, BAY63-2521) | Bayer | Hypertension, Pulmonary | | | | |
2015-005314-29: Randomized, open-label, two parallel group clinical trial, conducted under blinding evaluator conditions to compare the efficacy and tolerability of preservative-free formulation of Latanoprost 50µg/ml eye drops vs. Xalatan in patients with open-angle glaucoma or hypertension ocular. Ensayo clÃnico aleatorizado, no enmascarado para el paciente aunque enmascarado para el evaluador, con dos grupos en paralelos, para comparar la eficacia y tolerabilidad del colirio formulado con latanoprost 50µg/ml sin conservantes frente al colirio Xalatan en pacientes con glaucoma de ángulo abierto o hipertensión ocular. |
|
|
| Ongoing | 3 | 126 | Europe | Latanoprost 50 ug/ml, Eye drops, XALATAN | OMNIVISION GmbH, Omnivision GmbH | Open Angle Glaucoma or Ocular Hypertension Glaucoma de ángulo abierto o Hipertensión ocular, Open Angle Glaucoma or Ocular Hypertension Glaucoma de ángulo abierto o Hipertensión ocular, Diseases [C] - Eye Diseases [C11] | | | | |
2016-004365-16: An open-label study to learn if Bardoxolone Methyl is safe in the long-term in patients with pulmonary hypertension. Estudio abierto para comprobar si bardoxolona metilo es seguro a largo plazo en pacientes con hipertensión pulmonar |
|
|
| Ongoing | 3 | 414 | Europe | Bardoxolone Methyl, RTA 402, Capsule, hard | Reata Pharmaceuticals, Inc., Reata Pharmaceuticals, Inc. | Pulmonary Hypertension Hipertensión pulmonar, Raised blood pressure in the arteries that supply the lungs Aumento de la presión arterial en las arterias que suministran los pulmones, Diseases [C] - Cardiovascular Diseases [C14] | | | | |
2017-003934-10: A clinical study to investigate the long term safety of the drug macitentan in patients with pulmonary arterial hypertension and who were previously treated with macitentan in clinical studies. |
|
|
| Not yet recruiting | 3 | 150 | Europe | Macitentan, ACT-064992, Film-coated tablet, Opsumit | Actelion Pharmaceuticals Ltd, Actelion Pharmaceuticals Ltd. | Pulmonary arterial hypertension (PAH), PAH is a chronic condition in which the pressure in the blood vessels that go from the heart to the lungs (the pulmonary arteries) is higher than normal., Diseases [C] - Respiratory Tract Diseases [C08] | | | | |
2016-004035-21: A study to evaluate whether it is safe for patients with pulmonary arterialhypertension to temporarily change from selexipag tablets (Uptravi®) toselexipag given directly into a vein (intravenous selexipag) |
|
|
| Not yet recruiting | 3 | 20 | Europe | Selexipag, ACT-293987, Powder for solution for infusion | Actelion Pharmaceuticals Ltd, Actelion Pharmaceuticals Ltd | Pulmonary arterial hypertension, Pulmonary Arterial Hypertension is an increase in blood pressure in thepulmonary arteries leading to shortness of breath, dizziness, faintingand other symptoms., Diseases [C] - Cardiovascular Diseases [C14] | | | | |
2017-003688-37: Study, to investigate, if Tadalafil, a Phosphodiesterase-5 inhibitor, is benficial for the treatment of pulmonary hypertension due to left heart failure. Studie, um herauszufinden, ob Tadalafil, ein Phosphodiesterase-5 inhibitor, für die Behandlung von pulmonaler Hypertonie durch Linksherzversagen wirksam ist. |
|
|
| Ongoing | 3 | 372 | Europe | Tadalafil, 20mg, Capsule, hard, Tadalfil Stada 20mg Filmtablette | Philipps-Universität Marburg, Government, Stada | Combined post- and pre-capillary pulmonary hypertension and heart failure with preserved ejection fraction Kombinierte post- und präkapillare pulmonale Hypertonie in Verbindung mit Herzinsuffizienz mit erhaltener Ejektionsfraktion, Pulmonary hypertension in combination with left heart failure Lungenhochdruck in Kombination mit Linksherzschäche, Diseases [C] - Cardiovascular Diseases [C14] | | | | |
| Active, not recruiting | 3 | 24 | Europe, Japan, RoW | Riociguat (Adempas, BAY63-2521) | Bayer, Merck Sharp & Dohme LLC | Hypertension, Pulmonary | 03/20 | 07/26 | | |
NCT06448962: Phase 3 Study to Evaluate the Efficacy and Safety of Co-administrated AD-2021 and AD-2022 |
|
|
| Completed | 3 | 109 | RoW | AD-2021, AD-2022, AD-2021 Placebo, AD-2022 Placebo | Addpharma Inc. | Hypertension, Essential, Primary Hypercholesterolemia | 11/21 | 11/21 | | |
2019-000751-13: Trial to check efficacy and safety of Concor 5mg plus amlodipine 5mg in patients who have high blood pressure and whose blood pressure cannot be controlled under 5mg of amlodipine monotherapy. |
|
|
| Not yet recruiting | 3 | 400 | Europe | Concor (bisoprolol), Norvasc (Amlodipine), Film-coated tablet, Tablet | Fundacja “Centrum Rozwoju Medycyny”, Merck KGaA | hypertension, high blood pressure, Diseases [C] - Cardiovascular Diseases [C14] | | | | |
2020-004196-40: Efficacy and safety of GMRx2 compared to dual combinations for the treatment of high blood pressure Účinnost a bezpečnost GMRx2 ve srovnání s duálními kombinacemi při léčbě vysokého krevního tlaku |
|
|
| Not yet recruiting | 3 | 1500 | RoW, Europe | Triple TAI (GMRx2) Dose Version 2, Triple - TAI (GMRx2) Dose Version 3, Dual - TA Telmisartan / Amlodipine, Dual - TI Telmisartan / Indapamide, Dual - AI Amlodipine / Indapamide, Triple TAI (GMRx2) Dose Version 2, Triple - TAI (GMRx2) Dose Version 3, Dual - TA Telmisartan / Amlodipine, Dual - TI Telmisartan / Indapamide, Dual - AI Amlodipine / Indapamide, Capsule | George Medicines Pty Ltd, George Medicines | Hypertension, High blood pressure, Diseases [C] - Cardiovascular Diseases [C14] | | | | |
NCT06465264: To Assess Allisartan Isoproxil/Amlodipine in Patients With Essential Hypertension Uncontrolled With Amlodipine or Allisartan Isoproxil |
|
|
| Completed | 3 | 499 | RoW | Allisartan Isoproxil/Amlodipine group 1, Amlodipine group 1, Allisartan Isoproxil/Amlodipine group 2, Allisartan Isoproxil group 2 | Shenzhen Salubris Pharmaceuticals Co., Ltd. | Essential Hypertension | 08/22 | 02/23 | | |
2021-000147-45: A non-inferiority, randomized, investigator - masked, two-parallel group, phase III clinical trial, to evaluate the efficacy and safety of a preservative free formulation of latanoprost (YSLT) versus a reference drug (Xalatan®) in patients with primary open angle glaucoma (POAG) or ocular hypertension (OHT) – The COMET Study Μια μη-κατωτερότητας, τυχαιοποιημένη, τυφλή ως προς τον ερευνητή, δύο παράλληλων ομάδων, φάσης III κλινική δοκιμή, για την αξιολόγηση της αποτελεσματικότητας και της ασφάλειας ενός σκευάσματος λατανοπρόστης χωρίς συντηρητικό (YSLT) έναντι ενός φαρμάκου αναφοράς (Xalatan®) σε ασθενείς με πρωτογενές γλαύκωμα ανοικτής γωνίας (ΠΓΑΓ/POAG) ή οφθαλμική υπέρταση (ΟΥ/OHT) – Η Μελέτη COMET |
|
|
| Not yet recruiting | 3 | 170 | Europe | YSLT Latanoprost 50 μg/mL Eye Drop Solution, Xalatan 50 micrograms/mL Eye drops, solution, Eye drops, solution in single-dose container, Eye drops, solution, XALATAN | YONSUNG GMBH, YONSUNG GMBH | GLAUCOMA, OCCULAR HYPERTENSION Γλαύκωμα / Υψηλή πίεση στα μάτια, GLAUCOMA, OCCULAR HYPERTENSION Γλαύκωμα / Υψηλή πίεση στα μάτια, Diseases [C] - Eye Diseases [C11] | | | | |
NCT04830449: Clinical Efficacy and Safety Evaluation of HCP1904-2 in Essential Hypertension Patients |
|
|
| Completed | 3 | 122 | RoW | HCP1904-2, RLD2001-2 | Hanmi Pharmaceutical Company Limited | Hypertension | 08/21 | 08/21 | | |
NCT04820907: Clinical Efficacy and Safety Evaluation of HCP1904-1 in Essential Hypertension Patients |
|
|
| Completed | 3 | 123 | RoW | HCP1904-1, RLD2001-1 | Hanmi Pharmaceutical Company Limited | Hypertension | 09/21 | 09/21 | | |
2020-004891-16: A comparison of a single-pill combination of perindopril/indapamide/amlodipine/bisoprolol with perindopril,indapamide and amlodipine in patients with essential hypertension whose blood pressure remains high on perindopril, indapamide and amlodipine treatment. |
|
|
| Ongoing | 3 | 968 | Europe, RoW | S05179, S05179, Capsule, hard, Film-coated tablet, COVERSYL®, Norvasc®, FLUDEX® | Institut de Recherches Internationales Servier, Servier Portugal - Especialidades Farmaceuticas, Lda., INSTITUT DE RECHERCHES INTERNATIONALES SERVIER, ADIR, Servier Portugal - Especialidades Farmacêuticas, Lda., Servier Portugal - Especialidades Farmaceuticas, Lda. | Hypertension, High blood pressure, Diseases [C] - Cardiovascular Diseases [C14] | | | | |
2021-001498-21: A study to evaluate Sotatercept in Participants with PAH WHO FC III or FC IV at High Risk of Mortality Estudio para evaluar sotatercept en pacientes con HAP con una CF de la OMS III o IV y riesgo elevado de mortalidad |
|
|
| Not yet recruiting | 3 | 166 | Europe | Sotatercept, ACE-011, Lyophilisate for solution for injection | Acceleron Pharma Inc., ACCELERON PHARMA INC., Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ, USA, Acceleron Pharma Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ, USA, Acceleron Pharma Inc., Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ, USA, Acceleron Pharma Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ, USA | Pulmonary Arterial Hypertension (PAH) Hipertensión Arterial Pulmonar (HAP), Cardiovascular Disease Enfermedad Cardiovascular, Diseases [C] - Cardiovascular Diseases [C14] | | | | |
NCT06500689: To Assess Allisartan Isoproxil/Sustained-Release Indapamide in Patients With Essential Hypertension Uncontrolled With Allisartan Isoproxil |
|
|
| Completed | 3 | 366 | RoW | Allisartan Isoproxil/Sustained-Release Indapamide, Allisartan Isoproxil | Shenzhen Salubris Pharmaceuticals Co., Ltd. | Essential Hypertension | 11/23 | 05/24 | | |
NCT03992755: Extension Study for Participants in LIQ861 Trials to Evaluate the Long-term Safety of Dry Powder Inhalation of Treprostinil |
|
|
| Active, not recruiting | 3 | 92 | US | LIQ861 Inhaled Treprostinil, Inhaled treprostinil, Inhaled prostacyclin | Liquidia Technologies, Inc., Nuventra, Inc. | Primary Pulmonary Hypertension | 12/21 | 03/22 | | |
NCT04686643: Phase III Study to Evaluate the Efficacy and Safety of AGSAVI in Patients With Essential Hypertension |
|
|
| Not yet recruiting | 3 | 306 | NA | AGSAVI, S-amlodipine, Valsartan, Indapamide, AGLS, S-amlodipine, Valsartan | Ahn-Gook Pharmaceuticals Co.,Ltd | Hypertension | 02/22 | 05/22 | | |
2021-002297-11: Providing long-term treatment access in patients with pulmonary hypertension completing a parent study and having no other treatment access alternative |
|
|
| Not yet recruiting | 3 | 390 | Europe, RoW | Macitentan, Fixed dose combination of macitentan and tadalafil (JNJ-68150420), JNJ-67896062, CJNJ-68150420-ZZZ-G001 (ACT064992D), Film-coated tablet, Opsumit | Actelion Pharmaceuticals Ltd, Actelion Pharmaceuticals Ltd | Pulmonary Hypertension, Pulmonary hypertension (PH) is a disease associated with abnormally high pressure in the blood vessels of the lungs, Diseases [C] - Respiratory Tract Diseases [C08] | | | | |
NCT04659070: To Evaluate the Efficacy and Safety of Co-administrated Ezetimibe/Rosuvastatin and Telmisartan in Patients With Essential Hypertension and Primary Hypercholesterolemia |
|
|
| Recruiting | 3 | 156 | RoW | Experimental : Ezetimibe / Rosuvastatin + Telmisartan, Active comparator1 : Ezetimibe / Rosuvastatin, Active comparator2 : Telmisartan | Hanlim Pharm. Co., Ltd. | Primary Hypercholesterolemia, Hypertension | 05/22 | 05/22 | | |
NCT06416865: Efficacy and Safety of AJU-C52 in Essential Hypertension Patients |
|
|
| Recruiting | 3 | 190 | RoW | AJU-C52L, AJU-C52, C52R1L, C52R1M | AJU Pharm Co., Ltd. | Essential Hypertension | 12/22 | 08/24 | | |
A DUE, NCT03904693 / 2014-004786-25: Clinical Study to Compare the Efficacy and Safety of Macitentan and Tadalafil Monotherapies With the Corresponding Fixed-dose Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH) |
|
|
| Active, not recruiting | 3 | 187 | Europe, Canada, Japan, US, RoW | FDC macitentan/tadalafil, ACT-064992D, Macitentan 10 mg, ACT-064992, Tadalafil 40 mg, Placebo FDC, Placebo macitentan, Placebo tadalafil | Actelion | Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH) | 08/22 | 09/24 | | |
NCT05199129: Clinical Efficacy and Safety Evaluation of HCP1904-3 in Essential Hypertension Patients |
|
|
| Completed | 3 | 166 | RoW | HCP1904-3, RLD2001-1 | Hanmi Pharmaceutical Company Limited | Hypertension | 09/22 | 09/22 | | |
| Withdrawn | 3 | 60 | US | PRM-125 | PRM Pharma, LLC | Hypertension | 09/22 | 11/22 | | |
2021-006864-25: Inhaled iMatinib Pulmonary Arterial Hypertension Clinical Trial – Follow Up Long Term Extension (IMPAHCT-FUL) Ensayo clínico de Imatinib inhalado para la hipertensión arterial pulmonar - Extensión de seguimiento a largo plazo (IMPAHCT-FUL) |
|
|
| Ongoing | 3 | 462 | Europe | AV-101, Inhalation powder, hard capsule | Aerovate Therapeutics, Inc., Aerovate Therapeutics Inc | Pulmonary Arterial Hypertension (PAH) Hipertensión arterial pulmonar (HAP), PAH includes rare, chronic cardiopulmonary diseases involving common pathologic features of inappropriate cell growth resulting in increasedresistance to blood flow through the pulmonary vasculature. La HAP incluye patologías cardiopulmonares raras y crónicas que implican patologías de crecimiento celular inadecuado, provoca mayor resistencia al flujo sanguíneo a través de la vasculatura pulmonar., Diseases [C] - Cardiovascular Diseases [C14] | | | | |
NCT04730037: Clinical Trial to Investigate Safety and Efficacy of Edoxaban in Patients With CTEPH (KABUKI) |
|
|
| Completed | 3 | 74 | Japan | Edoxaban, Warfarin Potassium, Warfarin Potassium placebo, Edoxaban placebo | Kyushu University, Daiichi Sankyo Co., Ltd. | CTEPH | 03/23 | 06/23 | | |
NCT05475665: Clinical Efficacy and Safety Evaluation of Irbesartan High and Amlodipine Combined Therapy in Essential Hypertension Patients |
|
|
| Completed | 3 | 157 | RoW | Irbesartan/Amlodipine, Irbesartan | Handok Inc. | Essential Hypertension | 03/23 | 06/23 | | |
| Completed | 3 | 295 | Europe, US, RoW | Telmisartan 10 mg/amlodipine 1.25 mg/indapamide 0.625 mg, Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg, Placebo | George Medicines PTY Limited | Hypertension | 09/23 | 10/23 | | |
GMRx2_ACT, NCT04518293: Efficacy and Safety of GMRx2 Compared to Dual Combinations for the Treatment of Hypertension |
|
|
| Completed | 3 | 1385 | Europe, US, RoW | Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg, telmisartan 40 mg/amlodipine 5 mg/indapamide 2.5 mg, Telmisartan 20 mg/amlodipine 2.5 mg ., telmisartan 40 mg/amlodipine 5 mg, Telmisartan 20 mg/indapamide 1.25 mg, telmisartan 40 mg/indapamide 2.5 mg, Amlodipine 2.5 mg/indapamide 1.25 mg, amlodipine 5 mg/indapamide 2.5 mg | George Medicines PTY Limited | Hypertension | 08/23 | 09/23 | | |
NCT05331014: To Evaluate the Efficacy and Safety in Patients With Dyslipidemia and Hypertension |
|
|
| Completed | 3 | 155 | RoW | LivaloVA, JW0101+C2101, LivaloV, JW0101+C2102, VA, C2101 | JW Pharmaceutical | Dyslipidemia, Hypertension | 11/22 | 11/22 | | |
NCT02652429: Long-Term Extension Study of Inhaled Nitric Oxide (iNO) for PAH |
|
|
| Active, not recruiting | 3 | 22 | Canada, US | Inhaled Nitric Oxide, iNO | Bellerophon Pulse Technologies | Pulmonary Arterial Hypertension | 04/23 | 12/23 | | |
NCT05476354: Clinical Efficacy and Safety Evaluation of Irbesartan and Amlodipine Combined Therapy in Essential Hypertension Patients |
|
|
| Completed | 3 | 271 | RoW | Irbesartan/Amlodipine low, Irbesartan/Amlodipine high, Irbesartan | Handok Inc. | Essential Hypertension | 04/23 | 06/23 | | |
2019-003309-88: A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Ralinepag to Evaluate Safety and Effects on Exercise Capacity Assessed by Cardiopulmonary Exercise Testing in Subjects with World Health Organization Group 1 Pulmonary Hypertension Who Recently Initiated Therapy |
|
|
| Not yet recruiting | 3 | 193 | Europe | Ralinepag, APD811, Prolonged-release tablet | United Therapeutics Corporation, UNITED THERAPEUTICS CORPORATION, United Therapeutics Corporation | pulmonary arterial hypertension (PAH), high lung blood pressure, Diseases [C] - Cardiovascular Diseases [C14] | | | | |
CAPACITY, NCT04084678: A Study of Ralinepag to Evaluate Effects on Exercise Capacity by CPET in Subjects With WHO Group 1 PH |
|
|
| Terminated | 3 | 10 | Europe, Canada, US, RoW | Ralinepag, APD811, Placebo | United Therapeutics | PAH, Pulmonary Hypertension, Hypertension, Connective Tissue Disease, Familial Primary Pulmonary Hypertension, Vascular Diseases, Cardiovascular Diseases, Hypertension, Pulmonary, Lung Diseases, Respiratory Tract Disease, Pulmonary Arterial Hypertension | 04/23 | 04/23 | | |
| Completed | 3 | 361 | RoW | HCP1803-3, RLD2002, HPP2003-3, HPP2004 | Hanmi Pharmaceutical Company Limited | Hypertension | 06/23 | 06/23 | | |
REBUILD, NCT03267108: A Study to Assess Pulsed Inhaled Nitric Oxide in Subjects With Pulmonary Fibrosis at Risk for Pulmonary Hypertension |
|
|
| Terminated | 3 | 145 | Canada, US | INOpulse®, Placebo, Open Label Extension | Bellerophon Pulse Technologies | Pulmonary Fibrosis, Pulmonary Hypertension | 06/23 | 06/23 | | |
NCT05385770: Study to Evaluate and Compare the Efficacy and Safety of AZM and AML Combined and Alone in Mild-to-moderate Essential Hypertensive Subjects |
|
|
| Active, not recruiting | 3 | 890 | RoW | AZM X mg + AML Y mg, AZM X mg + AML Y' mg, AZM X' mg + AML Y mg, AZM X' mg + AML Y' mg, AZM X mg, AZM X' mg, AML Y mg, AML Y' mg | Celltrion | Essential Hypertension | 08/24 | 11/24 | | |
OLINDA, NCT05110898: Efficacy and Safety Study of the Fixed-dose Combination of Olmesartan + Indapamide When Compared to the Isolated Drugs in the Treatment of Hypertension. |
|
|
| Not yet recruiting | 3 | 400 | NA | fixed-dose of olmesartan 20mg/40 mg + indapamide 1,5 mg, Isolated drugs Olmesartan (20 mg or 40 mg) and Indapamide (1,5 mg) | Brainfarma Industria QuÃmica e Farmacêutica S/A | Hypertension, Hypertension,Essential | 08/23 | 10/23 | | |
NCT05931224: Clinical Trial to Evaluate the Efficacy and Safety of D064 and D702 Combination Therapy |
|
|
| Completed | 3 | 346 | RoW | D064, D702, placebo of D660, D064, D702 are consisted of antihypertensive agent., D660, placebo of D064, placebo of D702, D660 is consisted of antihypertensive agent. | Chong Kun Dang Pharmaceutical | Essential Hypertension | 05/24 | 05/24 | | |
NCT04927299: Efficacy and Safety of Losartan/Chlorthalidone vs Losartan/Hydrochlorothiazide in Essential Arterial Hypertension |
|
|
| Completed | 3 | 190 | RoW | Losartan/Chlorthalidone in fixed dose, LOS/CHLORTHA, Losartan + hydrochlorothiazide in fixed dose, LOS/HYDROCHLO | Laboratorios Silanes S.A. de C.V. | Essential Arterial Hypertension | 08/23 | 09/23 | | |
| Terminated | 3 | 14 | Europe, US, RoW | Presendin, Placebo | Invex Therapeutics Ltd., Premier Research Group plc, University Hospitals Birmingham Neuro Ophthalmology Reading Centre, Birmingham, UK, Iowa Visual Field Reading Centre, Iowa, USA | Idiopathic Intracranial Hypertension | 09/23 | 10/23 | | |
NCT05526703: Clinical Trial to Evaluate the Efficacy and Safety of D064 and D701 Combination Therapy |
|
|
| Recruiting | 3 | 108 | RoW | D064, D701, placebo of D012, D064, D701 are consisted of antihypertensive agent., D012, placebo of D064, placebo of D701, D012 is consisted of antihypertensive agent. | Chong Kun Dang Pharmaceutical | Essential Hypertension | 10/23 | 10/23 | | |
SPH3127-301, NCT05359068: Study to Evaluate the Efficacy and Safety of SPH3127 In Patients With Mild-moderate Essential Hypertension |
|
|
| Completed | 3 | 957 | RoW | SPH3127 tablet, Valsartan | Shanghai Pharmaceuticals Holding Co., Ltd | Essential Hypertension | 12/23 | 12/23 | | |
NCT05450601: A Study to Evaluate the Efficacy and Safety of HCP2102 in Essential Hypertension Patients |
|
|
| Completed | 3 | 249 | RoW | HCP2102-1, HPP2104-1, HCP2102-2, HPP2104-2, RLD2106-1, HPP2103-1, RLD2106-2, HPP2103-2 | Hanmi Pharmaceutical Company Limited | Hypertension | 12/23 | 12/23 | | |
NCT06153693: Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled and Resistant Hypertension |
|
|
| Recruiting | 3 | 1000 | Europe, Canada, US, RoW | Placebo, lorundrostat Dose 1, lorundrostat Dose 2 | Mineralys Therapeutics Inc. | Hypertension | 02/25 | 07/25 | | |
| Recruiting | 3 | 1000 | Europe, Canada, US, RoW | Ralinepag, APD811, Placebo | United Therapeutics | PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension, Hypertension, Connective Tissue Diseases, Familial Primary Pulmonary Hypertension, Vascular Diseases, Cardiovascular Diseases, Hypertension, Pulmonary, Lung Diseases, Respiratory Tract Disease | 12/24 | 12/24 | | |
| Active, not recruiting | 3 | 300 | US | Dehydrated alcohol, Ethanol, Peregrine System Kit (Sham Procedure) | Ablative Solutions, Inc. | Hypertension | 12/23 | 05/26 | | |
NCT04654507: Efficacy of Corticosteroids in Reducing Renal Scarring in Acute Pyelonephritis in Children |
|
|
| Recruiting | 3 | 120 | RoW | Dexamethasone Oral, corticosteroids, Placebo | Hamad Medical Corporation | Urinary Tract Infections in Children, Dexamethasone, Kidney Scarring, Acute Pyelonephritis, Hypertension in Children, Chronic Renal Failure, UTI | 12/23 | 12/24 | | |
UMBRELLA, NCT03422328: A Clinical Study to Investigate the Long-term Safety of the Drug Macitentan in Patients With Pulmonary Hypertension Who Were Previously Treated With Macitentan in Clinical Studies. |
|
|
| Completed | 3 | 147 | Europe, RoW | macitentan, ACT-064992, JNJ-67896062 | Actelion | Pulmonary Arterial Hypertension, Chronic Thromboembolic Pulmonary Hypertension | 12/23 | 12/23 | | |
2022-002524-12: A trial that aims to compare the efficacy and safety of two treatments for open-angle glaucoma or ocular hypertension. Both drugs contain the same active substance (Brinzolamide 10 mg/ml Eye Drops, Suspension). The patients will be followed for a certain period of time and will receive on a random principle either the new drug or the authorized drug. The trial will be conducted in several centers. The investigators will not know which patient is using a test and which reference product. Изпитване, което цели да сравни ефикасността и безопасността на две терапии за откритоъгълна глаукома или очна хипертония. Двете лекарства съдържат едно и също активно вещество (Бринзоламид 10 mg/ml капки за очи, суспензия). Пациентите ще бъдат проследени за определен период от време и ще получат на случаен принцип или новото лекарство, или вече разрешеното лекарство. Изпитването ще се проведе в няколко центъра. Изследователите няма да знаят кой пациент използва тест и кой референтен продукт. |
|
|
| Not yet recruiting | 3 | 244 | Europe | AZOPT, BRINZOLAMIDE 10MG/ML EYE DROPS SUSPENSION PRESERVATIVE FREE, Eye drops, suspension, AZOPT | AZAD Pharma AG, AZAD Pharma GmbH | GLAUCOMA , OCCULAR HYPERTENSION Глаукома, очна хипертония, GLAUCOMA , OCCULAR HYPERTENSION Глаукома, повишено вътреочно налягане, Diseases [C] - Eye Diseases [C11] | | | | |
NCT02932410 / 2016-001062-28: A Study to Assess Whether Macitentan Delays Disease Progression in Children With Pulmonary Arterial Hypertension (PAH) |
|
|
| Active, not recruiting | 3 | 300 | Europe, Canada, US, RoW | Macitentan, ACT-064992, Standard-of-care | Actelion | Pulmonary Arterial Hypertension | 11/23 | 12/24 | | |
NCT04668157: A Study of TAK-536 in Children From 2 to Less Than 6 Years Old With High Blood Pressure |
|
|
| Completed | 3 | 9 | Japan | TAK-536 | Takeda | Hypertension | 12/23 | 12/23 | | |
OPTION TREAT, NCT05920005: Candesartan Cilexetil + Chlorthalidone + Amlodipine Versus Exforge HCT®️ for Systemic Arterial Hypertension |
|
|
| Recruiting | 3 | 698 | RoW | candesartan cilexetil + chlorthalidone + amlodipine, Exforge HCT® (valsartan 160mg + hydrochlorothiazide 12.5mg + amlodipine 5mg) | Hospital Israelita Albert Einstein, Libbs Farmacêutica LTDA | Hypertension | 12/23 | 07/24 | | |
NCT05573477: Evaluation of Efficacy and Safety of ATB-1011+ATB-1012 Co-administration for Essential Hypertension and Type II Diabetes |
|
|
| Recruiting | 3 | 248 | RoW | ATB-1011, ATB-1012, ATB-1013, ATB-1011 placebo, ATB-1012 placebo, ATB-1013 placebo | Autotelicbio | Essential Hypertension, Diabetes Mellitus, Type 2 | 01/24 | 06/24 | | |
2023-000984-30: A Study of Macitentan in Japanese Pediatric Patients with Pulmonary Arterial Hypertension |
|
|
| Not yet recruiting | 3 | 7 | Japan | macitentan, ACT-064992/ JNJ-67896062, Dispersible tablet | Janssen Pharmaceutical K.K., Janssen Pharmaceutical K.K | Pulmonary arterial hypertension, Pulmonary Arterial Hypertension is a condition in which the pressure in the blood vessels going to the lungs (the pulmonary arteries) is higherthan normal, Diseases [C] - Cardiovascular Diseases [C14] | | | | |
NCT05503953: Phase III Study to Evaluate the Efficacy and Safety of AGSAVI in Patients With Essential Hypertension Inadequately Controlled With AGLS |
|
|
| Not yet recruiting | 3 | 306 | NA | AGSAVI, AGLS | Ahn-Gook Pharmaceuticals Co.,Ltd, Daehwa Pharmaceutical Co., Ltd. | Essential Hypertension | 02/24 | 07/24 | | |
NCT05643508: A Clinical Trial to Evaluate the Efficacy and Safety of Co-administration of DWC202206 and DWC202207 in Patients With Concomitant Hypertension and Hyperlipidemia |
|
|
| Not yet recruiting | 3 | 192 | NA | (D) DWC202206, (D) DWC202207, (P) DWC202206, (P) DWC202207 | Daewoong Pharmaceutical Co. LTD. | Hypertension, Hyperlipidemias | 03/24 | 03/24 | | |
NCT06141200: NW Roselle in Grade 1 Essential Hypertension: Phase III Clinical Trial |
|
|
| Not yet recruiting | 3 | 286 | NA | NW Roselle, Captopril 25Mg Tab | Natural Wellness Egypt | Essential Hypertension | 04/25 | 04/25 | | |
Bax24, NCT06168409: A Study to Investigate the Effect of Baxdrostat on Ambulatory Blood Pressure in Participants With Resistant Hypertension |
|
|
| Recruiting | 3 | 212 | Europe, Canada, US, RoW | Baxdrostat, CIN-107, Placebo | AstraZeneca | Resistant Hypertension | 04/25 | 04/25 | | |
| Active, not recruiting | 3 | 46 | Japan | Sotatercept, MK-7962, ActRIIA-IgG1Fc, ACE-011 | Merck Sharp & Dohme LLC | Pulmonary Arterial Hypertension | 03/24 | 08/25 | | |
HM_APOLLO, NCT06438172: A Study to Evaluate Efficacy and Safety of HCP1803 Compared to RLD2001-1 in Patients With Essential Hypertension |
|
|
| Recruiting | 3 | 220 | RoW | HCP1803-3, RLD2001-1, HPP2003-3, HPP2002-1 | Hanmi Pharmaceutical Company Limited | Hypertension | 06/25 | 06/25 | | |